From: Drug versus vaccine investment: a modelled comparison of economic incentives
Term | Definition |
---|---|
B | Budget threshold (regulator) |
CA ji | Cost avoided with technology j in year i |
c c | Annual cost of the disease per cohort before introduction of a new technology |
C ji | Cost associated with developing and selling technology j in year i |
d | Number of years after launch used for economic evaluations by the manufacturer |
E ji | Incremental quality-adjusted life-years gained from technology j in year i |
j | Technology indicator(j = 0 for treatment; j = 1 for prevention) |
l | Number of years required to develop technology before launch |
M ji | Gross margin for technology j in year i |
t | Time horizon in years used for economic evaluation (regulator) |
n c | Number of cohorts susceptible to the disease |
P ji | Price of technology j in year i |
Q ji | Quantity (demand) for technology j in year i |
r m | Discount rate used by manufacturer to evaluate investment |
r r | Discount rate used by regulator to evaluate new technologies |
s | Annual probability of children in susceptible cohorts becoming sick |
S ji | Sales of technology j in year i |
ψ t ( r ) | Discounting factor in the tth year, if the discount rate is r |